'Buckle up': Eli Lilly is set to 'dominate' the GLP-1 weight loss market in 2024 as Zepbound prescriptions soar, BMO says

"This is early validation that Lilly's franchise will dominate the landscape in 2024," BMO said of weekly drug prescription data.

https://markets.businessinsider.com/news/stocks/eli-lilly-stock-glp-1-weight-loss-zepbound-dominate-market-2024-1